<DOC>
	<DOCNO>NCT00666588</DOCNO>
	<brief_summary>This phase II trial study side effect best dose bortezomib see well work give together combination chemotherapy treat young patient recurrent , refractory , secondary acute myeloid leukemia ( AML ) . Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , idarubicin , cytarabine , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) together bortezomib may kill cancer cell</brief_summary>
	<brief_title>Bortezomib Combination Chemotherapy Treating Younger Patients With Recurrent , Refractory , Secondary Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine toxicity tolerability bortezomib combination standard-relapse AML therapy ( idarubicin/cytarabine etoposide/high-dose cytarabine ) pediatric young adult patient relapse primary-refractory secondary AML . II . To estimate complete response rate Arm A Arm B regimens . SECONDARY OBJECTIVES : I . To determine whether bortezomib inhibits proteasome activity , NF-kB activity induces apoptosis pathway protein leukemia myeloblast . II . To determine feasibility measure AML stem cell relapse recover bone marrow . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients stratify accord anthracycline*-equivalent cumulative exposure ( ≤ 400 mg/m² v &gt; 400 mg/m² ) . Patients assign 1 2 group . GROUP I ( efficacy phase , patient ≤ 400 mg/m² anthracycline-equivalent cumulative exposure - Closed 08/01/10 ) : Patients receive idarubicin IV 15 minute day 1-3 , low-dose cytarabine IV continuously day 1-7 , bortezomib IV day 1 , 4 , 8 . GROUP II ( dose-finding phase ( close 10/10 ) efficacy phase , patient &gt; 400 mg/m² anthracycline*-equivalent cumulative exposure ) : Patients receive etoposide IV 1 hour day 1-5 , high-dose cytarabine IV 1 hour twice daily day 1-5 , bortezomib IV day 1 , 4 , 8 . NOTE : * Anthracycline restriction longer require group 2 10/02/10 . All patient receive intrathecal cytarabine prior course 1 2 . In arm , treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) accord WHO classification At least 5 % blast bone marrow With without extramedullary disease To eligible dosefinding phase ( close 10/10 ) : Relapsed patient must meet following criterion : Must prior diagnosis AML , may NOT inv ( 16 ) ( 8 ; 21 ) cytogenetics May first subsequent relapse If first relapse , remission duration must less one year Refractory patient must meet following criterion : Must prior diagnosis AML May receive one attempt remission induction Patients treatmentrelated AML may previously treat untreated secondary AML To eligible efficacy phase : Relapsed patient must meet following criterion : Must prior diagnosis AML , restriction prior cytogenetics Must first relapse Must receive prior reinduction therapy Refractory patient must meet following criterion : Must prior diagnosis AML Must receive one attempt remission induction ( may consist two therapy course ) Patients treatmentrelated AML must previously untreated secondary AML No juvenile myelomonocytic leukemia acute promyelocytic leukemia ( APL ; FAB M3 ) Patients follow CNS status eligible absence neurologic symptom suggestive CNS leukemia , cranial nerve palsy : CNS 1 , define absence blast cerebral spinal fluid ( CSF ) cytospin preparation , regardless number WBCs CNS 2 , define presence &lt; 5/μL WBCs CSF cytospin positive blast , &gt; 5/uL WBCs negative Steinherz/Bleyer algorithm : CNS 2a : &lt; 10/μL RBCs ; &lt; 5/μL WBCs cytospin positive blast CNS 2b : ≥ 10/μL RBCs ; &lt; 5/μL WBCs cytospin positive blast CNS 2c : ≥ 10/μL RBCs ; ≥ 5/μL WBCs cytospin positive blast negative Steinherz/Bleyer algorithm Patients CNS3 disease ( presence ≥ 5/μL WBCs CSF cytospin positive blast [ absence traumatic lumbar puncture ] and/or clinical sign CNS leukemia ) eligible CNS toxicity ≤ grade 2 Lansky ( patient ≤ 16 year age ) Karnofsky ( patient &gt; 16 year age ) performance status ( PS ) 50100 % ECOG PS 02 No Down syndrome No Fanconi anemia , Kostmann syndrome , Shwachman syndrome , know bone marrow failure syndrome No evidence active graftvshost disease Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR serum creatinine base age/gender follow : 0.4 mg/dL patient 1 month &lt; 6 month age 0.5 mg/dL patient 6 month &lt; 1 year age 0.6 mg/dL patient 1 &lt; 2 year age 0.8 mg/dL patient 2 &lt; 6 year age 1 mg/dL patient 6 &lt; 10 year age 1.2 mg/dL patient 10 &lt; 13 year age 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) patient 13 &lt; 16 year age 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) patient ≥ 16 year age Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age ALT &lt; 3.0 time ULN age ( unless elevation due leukemia involvement ) Shortening fraction ≥ 27 % ECHO OR LVEF ≥ 50 % gated radionuclide Normal respiratory rate pulse oximetry &gt; 94 % room air FEV_1 ≥ 80 % predict FVC DLCO &gt; 50 % ( correct hemoglobin ) Patients unable perform pulmonary function test ( PFTs ) ( e.g. , young age ) exclude provided medical history significant prior pulmonary event chronic pulmonary disease ( e.g. , pneumonia require mechanical ventilation support , pulmonary GVHD , pneumonectomy , pulmonary toxin exposure ) Children histories resolve bronchiolitis , resolve viral pneumonia wellcontrolled asthma eligible , even unable perform PFTs Patients seizure disorder may enrol nonenzymeinducing anticonvulsant seizure wellcontrolled No uncontrolled infection No known allergy idarubicin , cytarabine , etoposide , boron , mannitol bortezomib Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Concurrent radiotherapy allow patient present chloroma produce threatens produce irreversible neurologic deficit Recovered prior chemotherapy , immunotherapy , radiotherapy More 2 week since prior cytotoxic chemotherapy ( 4 week nitrosoureas ) , except hydroxyurea , allow 24 hour prior first dose study drug , intrathecal chemotherapy , allow immediately administration study drug Prior steroid allow clinically indicated patient asthma Hydrocortisone methylprednisolone allow premedication patient history severe allergic reaction At least 7 day since prior biologic agent , steroid , retinoids , donor lymphocyte infusion without condition At least 2 week since prior local palliative radiotherapy ( small port ) At least 8 week since prior craniospinal radiotherapy ≥ 50 % radiation pelvis At least 6 week since prior bone marrow radiation At least 1 day since prior green tea containing product , product contain vitamin C , flavanoids antioxidant ( e.g. , vitamin , herbal supplement ) , food high vitamin C content No prior radiotherapy &gt; 25 % lung volume No prior totalbody irradiation part hematopoietic stem cell condition regimen At least 2 month since prior stem cell transplantation No concurrent graftvshost disease prophylactic medication No prior bortezomib proteasome inhibitor No concurrent investigational drug More 4 day since prior growth factor support platelet white cell number function No concurrent enzymeinducing anticonvulsant medication know potent inducer cytochrome P450 system , include phenytoin , carbamazepine , phenobarbital Concurrent benzodiazepine gabapentin allow No concurrent grapefruit juice bortezomib No concurrent cancer chemotherapy immunomodulating agent No concurrent corticosteroids antiemetic therapy Concurrent corticosteroid therapy allow treatment prophylaxis anaphylactic reaction , symptom cytarabine syndrome , treatment presumptive bortezomibinduced pulmonary toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>